glp-1 moa GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes Mechanism of action of GLP-1

Author contributions AFW: Conceptualization, Methodology, Software, Formal Analysis, Investigation, Visualization, Data curation, Writing original draft, Writing review and editing

[11] Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors

Lilly Trials

This episode is a call to action for patients and providers alike to rethink what subclinical really means, and to prioritize outcomes over outdated lab thresholds

10 or 15 mg once weekly) vs Reduce to tirzepatide 5 mg once weekly vs Placebo for 52 weeks (randomized 3:3:2 at week 60) Primary outcome: Percent change in bodyweight from baseline to week 112 Results: Primary outcome (percent change in bodyweight at week 112): Tirzepatide MTD -21.9%, Tirzepatide 5 mg -16.6%, Placebo -9.9% (estimated treatment difference vs placebo -12.0% for MTD and -6.6% for 5 mg

Visual outcome parameters did not change significantly from baseline to M6